TrialThe Journal of infection2022

Safety and immunogenicity of the inactivated whole-virus adjuvanted COVID-19 vaccine VLA2001: A randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults.

Rajeka Lazarus et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.